Cell & Gene Therapy drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags), By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others), By Method (In Vitro, Ex Vivo), By Region, & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.56 Billion
CAGR (2026-2031)	10.17%
Fastest Growing Segment	Prefilled Syringe
Largest Market	North America
Market Size (2031)	USD 2.79 Billion

Market Overview

The Global Cell & Gene Therapy drug Delivery Devices Market is projected to grow from USD 1.56 Billion in 2025 to USD 2.79 Billion by 2031 at a 10.17% CAGR. The global cell and gene therapy drug delivery devices market encompasses specialized technologies designed for the precise and efficient administration of therapeutic cells and genetic material to patients. Key drivers supporting market growth include substantial investment in cell and gene therapy research and development, an increasing number of regulatory approvals for advanced therapeutic products, and a robust pipeline of novel treatments progressing through clinical stages. For instance, according to the Alliance for Regenerative Medicine, the cell and gene therapy sector secured $11.1 billion in funding from 216 financings in 2025. Additionally, the European Medicines Agency's Committee for Advanced Therapies issued marketing authorization for Vyjuvek in April 2025 and adopted a positive draft opinion for Aucatzyl in May 2025, demonstrating accelerated regulatory progress.

A significant challenge impeding market expansion, however, is the inherent complexity and elevated manufacturing costs associated with producing these highly specialized drug delivery systems and their therapeutic payloads. Despite these hurdles, the industry continues to advance. According to the Alliance for Regenerative Medicine, two new cell and gene therapy blockbuster products emerged in 2025, underscoring the commercialization potential and increasing patient access to these innovative therapies.

Key Market Drivers

Increasing regulatory approvals for cell and gene therapies significantly propels the global cell and gene therapy drug delivery devices market. As more advanced therapeutic products receive authorization, the demand for precise and efficient delivery systems intensifies. These approvals validate the clinical utility of these therapies, encouraging further investment in associated delivery technologies. For instance, the FDA approved Waskyra® (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome on December 9, 2025, and Zevaskyn (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa on April 29, 2025. These landmark decisions highlight a growing acceptance of gene-corrected treatments, directly fostering the need for specialized devices capable of administering these complex biological payloads safely and effectively. The expanding array of approved therapies translates directly into a broader patient base requiring advanced delivery solutions.

Technological advancements in gene and cell delivery platforms represent another pivotal driver for market expansion. Innovations focus on enhancing the specificity, efficiency, and safety profiles of delivery methods, which are crucial for the successful application of cell and gene therapies. Developments include novel viral vector engineering and improvements in non-viral delivery systems. According to the National Institutes of Health, in April 2026, in the article "NIH-funded breakthrough shrinks CRISPR for precision delivery in the body," a research team discovered an enhanced CRISPR gene-editing system featuring the Al3Cas12f enzyme, small enough to fit into adeno-associated virus vectors for targeted delivery. Such advancements directly enable the treatment of a wider range of conditions and improve patient outcomes by facilitating more precise administration. Furthermore, this dynamic market reflects broader shifts in global research activity; according to the Alliance for Regenerative Medicine, in its Q3 2025 Sector Snapshot, the Asia-Pacific region surpassed North America in the number of clinical trials in 2025. This global expansion in research underscores the increasing need for sophisticated delivery devices across various regions.

Download Free Sample Report

Key Market Challenges

The inherent complexity and elevated manufacturing costs associated with producing specialized drug delivery systems and their therapeutic payloads represent a significant impediment to the growth of the global cell and gene therapy drug delivery devices market. These manufacturing processes often involve resource-intensive and difficult-to-scale legacy technologies, which inflate therapeutic costs and consequently limit patient access to these advanced treatments. The substantial capital required for scaling up advanced manufacturing technologies for both the therapies and their intricate delivery mechanisms creates a high financial barrier, directly restricting market penetration and broader adoption of these innovative solutions.

This financial burden directly hampers market expansion by increasing the overall cost of treatment for healthcare systems and patients. The necessity for significant investment to mitigate these high expenses is evident. For example, according to the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot, Kernal Bio was awarded $48 million to develop low-cost CAR-T cell therapies, indicating the substantial financial resources being directed towards addressing these foundational cost challenges. Such elevated manufacturing expenses for the therapeutic components ultimately translate into higher prices for the integrated therapy and its delivery device, thereby slowing the market's ability to achieve widespread commercialization and patient accessibility.

Key Market Trends

Enhanced patient-centric and home-use delivery systems are profoundly influencing the global cell and gene therapy drug delivery devices market by prioritizing user convenience and expanded access to treatments. This trend drives the development of devices that are less invasive, simpler to operate, and enable administration outside traditional clinical settings. Such advancements are crucial for therapies requiring frequent or long-term administration, where reducing the burden on patients and healthcare infrastructure becomes paramount. For instance, according to the Innovative Genomics Institute, July 2025, in "CRISPR Clinical Trials: A 2025 Update", the first personalized CRISPR treatment was administered to a patient, having been developed and delivered in just six months, illustrating the increasing emphasis on rapid, individualized patient solutions.

Automation and digitalization of delivery workflows represent another significant trend reshaping the market, primarily by enhancing manufacturing efficiency, scalability, and quality control. These innovations address the inherent complexity and high costs associated with producing cell and gene therapies, which typically involve intricate processes and highly specialized components. Integrating automated systems and digital tools into the manufacturing and administration pipeline streamlines operations, minimizes human error, and ensures consistency across batches. According to Lonza, December 11, 2025, in "Lonza's Cocoon® Platform Receives Advanced Manufacturing Technologies (AMT) Designation From The U.S. FDA", the Cocoon® Platform received Advanced Manufacturing Technologies Designation from the U.S. Food and Drug Administration, recognizing its automated and functionally closed design for cell therapy manufacturing, a development poised to facilitate regulatory processes and broader adoption of such technologies.

Segmental Insights

In the Global Cell & Gene Therapy Drug Delivery Devices Market, the prefilled syringe segment is emerging as the fastest-growing category. This rapid expansion is primarily driven by their inherent advantages in administering highly sensitive and often expensive cell and gene therapies. Prefilled syringes significantly reduce the risk of medication errors and contamination through their ready-to-use, pre-measured design, ensuring precise dosing crucial for these advanced treatments. Furthermore, they enhance patient safety, convenience, and adherence by facilitating self-administration at home, aligning with the growing trend towards decentralized care. The ability to minimize drug overfill and wastage also offers economic benefits, particularly vital for high-value biopharmaceuticals. This aligns with regulatory bodies encouraging patient-centric and efficient delivery solutions.

Regional Insights

North America dominates the Global Cell & Gene Therapy Drug Delivery Devices Market, primarily driven by its highly developed biopharmaceutical industry with significant investments in research and development initiatives. The region benefits from world-class medical and research institutions, alongside advanced healthcare infrastructure, which facilitates the clinical translation and adoption of these specialized therapies. A crucial factor is the supportive regulatory environment, notably from the U.S. Food and Drug Administration, which employs expedited pathways such as the Regenerative Medicine Advanced Therapy designation to accelerate the development and approval of innovative cell and gene therapies. This comprehensive ecosystem fosters continuous innovation and drives the demand for specialized drug delivery solutions.

Recent Developments

• In April 2026, a research team funded by the National Institutes of Health announced a breakthrough in CRISPR gene-editing technology. The team identified and engineered Al3Cas12f, a naturally occurring enzyme small enough to be incorporated into adeno-associated virus vectors, which are leading targeted delivery methods for gene therapies. This advancement addresses a significant limitation in CRISPR technology, where commonly used gene-editing proteins are often too large for effective targeted delivery systems inside the body. This innovation is expected to significantly expand the clinical applications for in vivo gene therapy delivery.
• In May 2025, Entos Pharmaceuticals Inc. and CureDuchenne Ventures announced a collaboration focused on developing a novel muscle-targeting therapy for Duchenne muscular dystrophy. CureDuchenne Ventures invested $1 million to support Entos Pharmaceuticals' efforts. The collaboration leverages Entos' proprietary Fusogenix PLV (proteolipid vesicle) delivery platform. This platform aims to deliver full-length dystrophin, a protein deficient in individuals with Duchenne muscular dystrophy, directly into cells. This partnership highlights an advancement in specialized delivery platforms for gene therapies within the global cell and gene therapy drug delivery devices market.
• In March 2025, Neurotech Pharmaceuticals received FDA approval for Encelto, an encapsulated cell therapy implant designed as the first treatment for idiopathic macular telangiectasia type 2 (MacTel). This implant acts as a novel platform for sustained protein delivery directly into the eye. The approval was supported by phase 3 clinical trial data showing a notable reduction in photoreceptor degeneration. Encelto represents a significant advancement in drug delivery devices for cell and gene therapies, offering a new approach for managing retinal diseases by providing continuous therapeutic agent secretion. The product was anticipated to become available in the U.S. by mid-2025.
• Throughout 2025, advancements continued in the field of micro robotics for targeted drug delivery. These innovations focused on developing tiny, soft robots capable of navigating narrow spaces within the human body to precisely dispense medicines. Researchers worked on improving the control of robotic dosing and addressing potential immune system responses. Initial trials demonstrated that grain-sized soft robots could transport multiple drugs and release them in reprogrammable orders and doses, controlled by magnetic fields. Such developments are crucial for enhancing the precision and efficiency of drug delivery systems within the cell and gene therapy sector.

Key Market Players

• Becton Dickinson and Company
• Novartis AG
• Amgen Inc.
• Kite Pharma Inc.
• Pfizer Inc.
• Bausch & Lomb Incorporated
• Bluebird bio Inc.
• Castle Creek Biosciences Inc
• Dendreon Pharmaceuticals LLC
• Helixmith Co. Ltd

By Type	By Route of Administration	By Method	By Region
Subretinal Injection Cannula Extension Tube Intravenous Catheter Sterile Insulin Syringe Prefilled Syringe Infusion Bags	Oral Intravenous Ocular Transdermal Others	In Vitro Ex Vivo	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cell & Gene Therapy drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell & Gene Therapy drug Delivery Devices Market , By Type:

• Subretinal Injection Cannula
• Extension Tube
• Intravenous Catheter
• Sterile Insulin Syringe
• Prefilled Syringe
• Infusion Bags

• Cell & Gene Therapy drug Delivery Devices Market , By Route of Administration:

• Oral
• Intravenous
• Ocular
• Transdermal
• Others

• Cell & Gene Therapy drug Delivery Devices Market , By Method:

• In Vitro
• Ex Vivo

• Cell & Gene Therapy drug Delivery Devices Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE